FANTINI, MASSIMO CLAUDIO
 Distribuzione geografica
Continente #
EU - Europa 66.214
NA - Nord America 6.400
AS - Asia 3.621
SA - Sud America 912
AF - Africa 96
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 4
Totale 77.271
Nazione #
IT - Italia 64.996
US - Stati Uniti d'America 6.284
SG - Singapore 1.563
CN - Cina 967
BR - Brasile 715
VN - Vietnam 438
SE - Svezia 332
FI - Finlandia 260
HK - Hong Kong 169
FR - Francia 159
DE - Germania 145
GB - Regno Unito 121
IN - India 97
AR - Argentina 67
BD - Bangladesh 50
CA - Canada 48
MX - Messico 42
EC - Ecuador 40
IQ - Iraq 40
NL - Olanda 37
TR - Turchia 34
KR - Corea 33
CO - Colombia 32
PK - Pakistan 29
ZA - Sudafrica 28
ID - Indonesia 27
AT - Austria 26
UZ - Uzbekistan 25
JP - Giappone 23
AU - Australia 22
PL - Polonia 20
EG - Egitto 17
MA - Marocco 17
PY - Paraguay 16
SA - Arabia Saudita 15
UA - Ucraina 15
ES - Italia 14
PH - Filippine 14
CZ - Repubblica Ceca 12
VE - Venezuela 12
KZ - Kazakistan 11
MY - Malesia 11
RU - Federazione Russa 11
JO - Giordania 9
PE - Perù 9
AZ - Azerbaigian 8
CL - Cile 8
IE - Irlanda 8
IL - Israele 8
LB - Libano 8
NP - Nepal 8
CH - Svizzera 7
HU - Ungheria 7
KE - Kenya 7
OM - Oman 7
TN - Tunisia 7
DK - Danimarca 6
DO - Repubblica Dominicana 6
GR - Grecia 5
JM - Giamaica 5
KG - Kirghizistan 5
UY - Uruguay 5
BG - Bulgaria 4
DZ - Algeria 4
ET - Etiopia 4
GT - Guatemala 4
LT - Lituania 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
BO - Bolivia 3
GY - Guiana 3
HN - Honduras 3
IR - Iran 3
RO - Romania 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BB - Barbados 2
BE - Belgio 2
BH - Bahrain 2
FJ - Figi 2
IS - Islanda 2
KW - Kuwait 2
LU - Lussemburgo 2
LV - Lettonia 2
NI - Nicaragua 2
QA - Qatar 2
SN - Senegal 2
UG - Uganda 2
AM - Armenia 1
AO - Angola 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
KH - Cambogia 1
Totale 77.255
Città #
Cagliari 61.185
Uta 3.531
Fairfield 883
Singapore 772
Ashburn 656
Woodbridge 403
Seattle 381
San Jose 366
Dallas 350
Houston 325
Cambridge 318
Boardman 314
Wilmington 297
Nyköping 253
Helsinki 228
Los Angeles 150
Ho Chi Minh City 140
Beijing 139
Hong Kong 133
Santa Clara 127
Council Bluffs 117
Ann Arbor 108
Lauterbourg 105
Boston 98
New York 93
Hanoi 84
Jacksonville 79
Hefei 69
Shanghai 68
Buffalo 59
São Paulo 58
Rome 47
Chandler 46
San Diego 45
Dearborn 37
Hangzhou 36
Munich 36
The Dalles 35
Dong Ket 32
Redwood City 31
Frankfurt am Main 30
Orem 30
Rio de Janeiro 30
Seoul 28
Chicago 27
London 27
Guangzhou 25
Milan 25
Montreal 23
Atlanta 22
Tashkent 21
Amsterdam 20
Nuremberg 20
Da Nang 19
Tokyo 18
Baghdad 17
Lappeenranta 17
Melbourne 17
Mountain View 17
Nanjing 17
Haiphong 16
Belo Horizonte 15
Chennai 15
Curitiba 15
Denver 15
Guayaquil 15
Tianjin 15
Vienna 15
Brasília 14
Brooklyn 14
Johannesburg 14
Mexico City 14
Turku 14
Warsaw 14
Düsseldorf 13
Phoenix 13
Redondo Beach 13
Salt Lake City 13
Ankara 12
Biên Hòa 11
Medellín 11
Poplar 11
San Francisco 11
Stockholm 11
Zhengzhou 11
Brno 10
Norwalk 10
Quito 10
Toronto 10
Wuhan 10
Asunción 9
Guarulhos 9
Jeddah 9
Buenos Aires 8
Hyderabad 8
Kilburn 8
Kunming 8
New Delhi 8
Nova Iguaçu 8
Redmond 8
Totale 73.152
Nome #
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.130
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.105
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history 1.924
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.637
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.585
RORGT-expressing tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells 1.581
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.545
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.337
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.333
Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study 1.309
Multidimensional Impact of Mediterranean Diet on IBD Patients 1.274
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 1.267
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 1.210
Quercetin and its derivates as antiviral potentials: A comprehensive review 1.207
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.175
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases 1.130
Reciprocal regulation between Smad7 and Sirt1 in the gut 1.074
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.061
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide 1.056
The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation 1.029
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 1.014
Heligmosomoides polygyrus bakeri infection decreases Smad7 expression in intestinal CD4+ T cells, which allows TGF-b to induce IL-10–producing regulatory T cells that block colitis 1.003
Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down? 992
Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence 968
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 958
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 951
Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death 937
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth 888
A functional role for Smad7 in sustaining colon cancer cell growth and survival 884
Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation 883
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 842
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 842
Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis 757
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages 752
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 722
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 716
Immune system and gut microbiota senescence in elderly IBD patients 707
Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis 705
Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells 693
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression 671
Smad7 expression in T cells prevents colitis-associated cancer 649
The impact of translational research on gastroenterology 634
Reprogramming the immune system in IBD 629
Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study 628
null 617
Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy 591
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies 581
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations 562
Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression 561
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine 554
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer 546
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies 544
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study 533
Intestinal inflammation and colorectal cancer: a double-edged sword? 528
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 525
The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6 500
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases 498
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 498
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via a p38 Map kinase-dependent induction of SOCS-3 497
Regulation of homeostasis and inflammation in the intestine 494
Diagnostic delay in adult coeliac disease: An Italian multicentre study 490
Inhibitory Effect of Quercetin on Oxidative Endogen Enzymes: A Focus on Putative Binding Modes 487
High resolution colonoscopy in live mice 485
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus 478
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase 478
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut 477
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid 468
Drug insight: novel small molecules and drugs for immunosuppression 466
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis 461
New players in the cytokine orchestra of inflammatory bowel disease 460
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 458
IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes 453
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation 453
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis 443
Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis 441
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells 437
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy 432
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa 431
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 425
IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 421
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling 419
IL-21 comes of age as a regulator of effector T cells in the gut 413
Regulation of gut inflammation and th17 cell response by interleukin-21 411
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease 411
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 407
Cytokines: from gut inflammation to colorectal cancer 405
In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells 396
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes 395
TGF-beta as a T cell regulator in colitis and colon cancer 394
Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 394
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study 391
Role of interleukin-21 in inflammation and allergy 391
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells 390
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease 385
Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy 382
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 379
Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum 378
Telemedicine and remote screening for COVID-19 in inflammatory bowel disease patients: results from the SoCOVID-19 survey 374
IL-6 signaling promotes tumor growth in colorectal cancer 372
EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation 365
Totale 73.019
Categoria #
all - tutte 119.961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.961


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.022 0 0 0 0 0 0 0 0 0 0 369 653
2021/20225.699 362 462 288 255 479 473 250 494 442 691 871 632
2022/20239.989 797 1.203 1.202 524 662 1.418 640 939 577 649 811 567
2023/202412.823 522 435 373 894 1.421 2.156 2.253 819 617 811 1.347 1.175
2024/202525.121 5.286 6.813 3.029 3.188 1.712 1.709 2.055 105 394 334 230 266
2025/20268.672 455 283 988 1.174 579 652 2.559 483 628 826 45 0
Totale 77.685